← Back to Screener
Immunic, Inc. Common Stock (IMUX)
Price$1.00
Favorite Metrics
Price vs S&P 500 (26W)19.62%
Price vs S&P 500 (4W)-9.30%
Market Capitalization$144.82M
All Metrics
Book Value / Share (Quarterly)$0.11
P/TBV (Annual)0.43x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.71
Price vs S&P 500 (YTD)105.22%
EPS (TTM)$-0.69
10-Day Avg Trading Volume2.05M
EPS Excl Extra (TTM)$-0.69
EPS (Annual)$-0.62
ROI (Annual)-545.37%
Cash / Share (Quarterly)$0.13
ROA (Last FY)-404.01%
EBITD / Share (TTM)$-0.63
ROE (5Y Avg)-215.14%
Cash Flow / Share (Annual)$-0.71
P/B Ratio13.79x
P/B Ratio (Quarterly)8.28x
Net Income / Employee (Annual)$-1
Net Interest Coverage (TTM)-15.34x
ROA (TTM)-264.95%
EPS Incl Extra (Annual)$-0.62
Current Ratio (Annual)0.75x
Quick Ratio (Quarterly)0.56x
3-Month Avg Trading Volume2.94M
52-Week Price Return20.91%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.09
52-Week High$1.51
EPS Excl Extra (Annual)$-0.62
CapEx CAGR (5Y)1.43%
Tangible BV CAGR (5Y)17.83%
26-Week Price Return23.61%
Quick Ratio (Annual)0.56x
13-Week Price Return67.67%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)0.75x
Enterprise Value$129.333
Book Value / Share Growth (5Y)-48.16%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.13
3-Month Return Std Dev101.84%
Net Income / Employee (TTM)$-1
ROE (Last FY)-545.37%
EPS Basic Excl Extra (Annual)$-0.62
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.69
ROI (TTM)-370.35%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.89
Price vs S&P 500 (52W)-8.92%
Year-to-Date Return107.87%
5-Day Price Return-13.95%
EPS Normalized (Annual)$-0.62
ROA (5Y Avg)-196.68%
Month-to-Date Return0.00%
Cash Flow / Share (TTM)$-3.00
EBITD / Share (Annual)$-0.63
ROI (5Y Avg)-215.14%
EPS Basic Excl Extra (TTM)$-0.69
P/TBV (Quarterly)1.01x
P/B Ratio (Annual)4.89x
Book Value / Share (Annual)$0.20
Price vs S&P 500 (13W)66.99%
Beta1.36x
Revenue / Share (TTM)$0.00
ROE (TTM)-370.35%
52-Week Low$0.51
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.27
4.27
4.27
4.33
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IMUXImmunic, Inc. Common Stock | — | — | — | — | $1.00 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
Immunic is a clinical-stage biopharmaceutical company developing selective oral therapies for chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, multiple sclerosis, and psoriasis. The company's pipeline includes three lead candidates: IMU-838 (immune cell metabolism inhibitor), IMU-935 (RORγt pathway modulator), and IMU-856 (intestinal barrier restoration). These therapies target large patient populations with significant unmet treatment needs.